Filter Results

Select search scope: search across all journals or within the current journal

Search this journal

Enter search terms…

Advanced search

/

About

About Sage
About Sage Journals
Privacy Policy
Terms of Use
Contact Us
Help

Information for

Authors
Editors
Librarians
Researchers
Reviewers
Frequently asked questions

All content on this site: Copyright © 2026 Sage Publications. All rights reserved. This website is technically supported and operated by China National Publications Import and Export (Group) Co., Ltd. 京ICP备09090397号-11

Comment: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19

Annals of Pharmacotherapy

Impact Factor: 2.5 / 5-Year Impact Factor: 2.7

Journal Homepage Submission guidelines

Restricted access

Letter

First published online September, 2023

Comment: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19

and

Volume 57, Issue 9

https://doi.org/10.1177/10600280221144932

Abstract

Get full access to this article

View all access options for this article.

References

1.

Reid

NK

Joyner

KR

Lewis-Wolfson

TD.

Baricitinib versus tocilizumab for the treatment of moderate to severe COVID-19. Ann Pharmacother. Published online October 29, 2022. doi:10.1177/10600280221133376

2.

Joob

B

Wiwanitkit

V.

Letter to the editor: coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. J Prev Med Public Health. 2020;53(2):70. doi:10.3961/jpmph.20.065

Browse journal

Current issue OnlineFirst All issues

Similar articles

Restricted access

Self-Induced DMSO Toxicity

Restricted access

The No-B.S. Pharm.D. Degree

Restricted access

A Comparison of Automated Infusion Device Technology to Prevent Medication Errors in Pediatric and Adult Intensive Care Unit Patients

Restricted access

Perforation of the Native Urinary Bladder as a Complication of Intermittent Self Catheterisation